News coverage about MacroGenics (NASDAQ:MGNX) has been trending somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. MacroGenics earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.6401112396323 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

MacroGenics (NASDAQ MGNX) opened at $28.59 on Friday. The company has a market capitalization of $1,082.46, a PE ratio of -40.84 and a beta of 2.52. MacroGenics has a 1-year low of $14.36 and a 1-year high of $32.74.

How to Become a New Pot Stock Millionaire

A number of research firms have recently issued reports on MGNX. Morgan Stanley reiterated an “equal weight” rating and issued a $26.00 target price (up previously from $18.00) on shares of MacroGenics in a research note on Wednesday, March 14th. BidaskClub upgraded MacroGenics from a “hold” rating to a “buy” rating in a research note on Thursday, March 8th. HC Wainwright began coverage on MacroGenics in a research note on Monday, March 5th. They issued a “buy” rating and a $38.00 target price for the company. ValuEngine upgraded MacroGenics from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. Finally, Zacks Investment Research lowered MacroGenics from a “hold” rating to a “sell” rating in a research note on Friday, February 23rd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $29.78.

In related news, SVP Eric Blasius Risser sold 1,000 shares of the stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $31.08, for a total value of $31,080.00. Following the completion of the transaction, the senior vice president now owns 10,100 shares of the company’s stock, valued at $313,908. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Jon Marc Wigginton sold 5,000 shares of the stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $20.00, for a total value of $100,000.00. The disclosure for this sale can be found here. Insiders sold 42,967 shares of company stock valued at $1,098,005 in the last three months. 8.30% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect MacroGenics (MGNX) Stock Price” was first reported by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://www.watchlistnews.com/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-macrogenics-mgnx-stock-price/1958994.html.

About MacroGenics

MacroGenics, Inc, a biopharmaceutical company, focuses on the discovery and development of antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company's advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers.

Insider Buying and Selling by Quarter for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.